Hidradenitis Suppurativa
📧 Sign up to get email alerts when something new happens for Hidradenitis Suppurativa.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 2]
Phase 2 trial studying IFX-1 for hidradenitis suppurativa has been completed with results posted.
-
FDA approval · 2021-02-24FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.
-
EMA withdrawal · 2021-01-29EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH
The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa [Phase 2]
A Phase 2 placebo-controlled trial evaluated the safety of INCB054707 in participants with hidradenitis suppurativa; results have been poste…
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-05-20Clinical Trial Update: A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa [Phase 2]
Phase 2 trial summary of INCB054707 in hidradenitis suppurativa completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-05-14Clinical Trial Update: Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically [Phase 4]
Phase 4 trial evaluating safety and efficacy of adalimumab (Humira) for hidradenitis suppurativa peri-surgically has completed with results …
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa [Phase 1, Phase 2]
Clinical trial evaluating hydroxychloroquine for hidradenitis suppurativa has completed Phase 1 and Phase 2 with results posted.
-
CLINICAL_TRIALS trial_result · 2019-08-09Clinical Trial Update: Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
Post-marketing observational study assessing quality of life in Swedish patients with hidradenitis suppurativa completed with results posted…
-
FDA approval · 2019-06-13FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients [Phase 2]
Phase 2 trial evaluating CJM112 in hidradenitis suppurativa completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Treatment of Moderate Hidradenitis Suppurativa [Phase 2]
Phase 2 clinical trial update for treatment of moderate hidradenitis suppurativa.
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa [Phase 2]
A single-center Phase 2 trial evaluating apremilast for hidradenitis suppurativa has completed.
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
EMA withdrawal · 2019-03-05EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.
Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa [Phase 3]
Open-label Phase 3 trial evaluating adalimumab in Japanese subjects with hidradenitis suppurativa has completed with results posted.
-
CLINICAL_TRIALS research · 2019-02-08Clinical Trial Update: Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS [Phase 4]
This Phase 4 trial update assesses the cost-effectiveness of adalimumab with surgery versus adalimumab alone in hidradenitis suppurativa.
-
FDA approval · 2018-10-30FDA Approved: ADALIMUMAB — Original Application (Sandoz Inc)
FDA approved the original application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc. The approval covers the same indication…
-
FDA approval · 2018-10-16FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
-
CLINICAL_TRIALS research · 2018-07-26Clinical Trial Update: Hidradenitis Suppurativa and Periodontal Diseases
A ClinicalTrials entry sponsored by CHU de Reims examining hidradenitis suppurativa and periodontal disease, with the study status currently…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis [Phase 2]
This phase 2 trial reports on the short-term safety and efficacy, and explores the mechanism of action, of apremilast in patients with moder…
-
CLINICAL_TRIALS trial_result · 2018-06-25Clinical Trial Update: Microwave Ablation in Mild Axillary Hidradenitis Suppurativa [NA]
A clinical trial evaluating microwave ablation for mild axillary hidradenitis suppurativa has been terminated.
-
FDA approval · 2018-03-15FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2018-03-09Clinical Trial Update: A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. [NA]
This update reports the results of a randomized controlled trial evaluating intralesional Triamcinolone for hidradenitis suppurativa, with t…
-
FDA approval · 2017-12-01FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) submitted by Eli Lilly and Company, resulting in an expanded label for additi…